Oaktree Acquisition Corp. Iii Life Sciences (OACC) Stock Price & Analysis
Oaktree Acquisition Corp. Iii Life Sciences (OACC) rose 0.00% to USD 10.71 as of July 26, 2026 at 07:26 UTC, according to Nexqual real-time market data.
OACC last closed at USD 10.71; the session ranged USD 10.71–10.71 on volume of 9 shares. Market capitalization is $263.28M, with a 52-week range of USD 10.3–10.74 (NGM). Source: Nexqual, July 26, 2026 at 07:26 UTC.
Key Statistics (as of July 26, 2026 at 07:26 UTC)
| Price | USD 10.71 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 10.71 |
| Open | USD 10.7 |
| Day Range | USD 10.71 – 10.71 |
| 52-Week Range | USD 10.3 – 10.74 |
| Volume | 9 shares |
| Market Cap | $263.28M |
| Exchange | NGM |
Technical Analysis (OACC)
Nexqual's technical model rates OACC "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 26, 2026 at 07:26 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.91 (neutral) |
| vs SMA50 | Above (USD 10.68) |
| MACD | 0.01 (positive) |
Analyst Ratings (OACC)
Wall Street analysts rate OACC "None", per Nexqual as of July 26, 2026 at 07:26 UTC.
| Consensus Rating | None |
|---|
Earnings (OACC)
Source: Nexqual, July 26, 2026 at 07:26 UTC.
Financials & Fundamentals (OACC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.87 |
| Total Cash | $1.28M |
| Total Debt | $11,824 |
Source: Nexqual, July 26, 2026 at 07:26 UTC.
Financial Health Score (OACC)
Nexqual rates Oaktree Acquisition Corp. Iii Life Sciences's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 07:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $1M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$505K |
| Efficiency | Mixed — No data |
Ownership (OACC)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +90.68% |
| Shares Outstanding | 19.78M |
| Float | 18.46M |
| Short % of Float | +0.06% |
Source: Nexqual, July 26, 2026 at 07:26 UTC.
Leadership (OACC)
Oaktree Acquisition Corp. Iii Life Sciences is led by Zaid Pardesi (age 42), CEO & Director, per Nexqual as of July 26, 2026 at 07:26 UTC.
| CEO & Director | Zaid Pardesi (age 42) |
|---|---|
| CFO, Principal Accounting & Principal Financial Officer | George A. Martinez (age 40) |
Major Backers & Investors (OACC)
Notable institutional backers of Oaktree Acquisition Corp. Iii Life Sciences include AQR Arbitrage LLC, Decagon Asset Management LLP, Fort Baker Capital Management LP, according to Nexqual as of July 26, 2026 at 07:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AQR Arbitrage LLC | 6.69% |
| Decagon Asset Management LLP | 5.07% |
| Fort Baker Capital Management LP | 5.05% |
| Empyrean Capital Partners, LP | 4.55% |
| Shaw D.E. & Co., Inc. | 4.36% |
| Boussard & Gavaudan Investment Management LLP | 3.64% |
| Linden Advisors LP | 3.03% |
| Sculptor Capital LP | 2.68% |
Source: Nexqual, July 26, 2026 at 07:26 UTC.
From Oaktree Acquisition Corp. Iii Life Sciences's Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- III Life Sciences does not have significant operations.
- The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
- It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NPAC | New Providence Acquisition Corp | USD 10.39 | ▲ 0% |
| LWAC | LightWave Acquisition Corp. | USD 10.25 | ▲ 0.2% |
| TWLV | Twelve Seas Investment Company | USD 10.02 | ▲ 0.3% |
| GPAT | GP-Act III Acquisition Corp. | USD 10.91 | ▼ 0.18% |
| SDHI | Siddhi Acquisition Corp | USD 10.46 | ▲ 0.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 07:26 UTC. This page is informational and not investment advice.